KR880010776A - 림포킨 및 이중-가닥 rna의 상승 작용화 조성물 - Google Patents
림포킨 및 이중-가닥 rna의 상승 작용화 조성물 Download PDFInfo
- Publication number
- KR880010776A KR880010776A KR1019880002204A KR880002204A KR880010776A KR 880010776 A KR880010776 A KR 880010776A KR 1019880002204 A KR1019880002204 A KR 1019880002204A KR 880002204 A KR880002204 A KR 880002204A KR 880010776 A KR880010776 A KR 880010776A
- Authority
- KR
- South Korea
- Prior art keywords
- dsrna
- interleukin
- lymphokine
- therapeutic composition
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1도는 재결합된 인터류킨-2(rIL-2) 및 림포칸 활성 킬러(LAK)세포로 하는 현재 종양 치료법을 나타낸 도식도, 제 2도는 여러 가지의 IL-2 투여량과 독성 및 투여한 재독성을 비교한 개괄적인 임상데이타를 나타낸 막대그래프, 제 3A도 및 제 3B도는 IL-2의 투여량을 다르게 했을때의 세포독소와 dsRNA를 일정하게 투여했을 때의 세포독소를 비교한 막대 그래프.
Claims (11)
- 종양 또는 바이러스 감염된 또는 면역 조절 기능을 잃은 세포의 숫자를 줄이기 위하여 dsRNA, 림포킨 및, 선택적으로 사이클로옥시지나제 활성제를 억제하는 물질을 이루어진 결합체를 사람에게 투여하는 것을 포함하는 사람을 치료하는 방법.
- 제 1항에 있어서, 상기 dsRNA는 잘못 짝지은 dsRNA이며, 바람직하게는 rIn. (C12U)n의 일반식을 가지는 것을 특징하는 방법.
- 제 2항에 있어서, 상기 림포킨은 인터페론 또는 인터류킨인 것을 특징으로 하는 방법.
- 상기 항 중 어느 한 항에 있어서, 사이클로옥시지나제를 억제하는 물질을 또한 프로스타글라딘 방출 및 생성된 NK 세포 감소 조절응답을 폐기하는 것을 특징으로 하는 방법.
- 상기 항 중 어느 한 항에 있어서, 인체 중의 NK 및 LAK세포의 농도는 독성을 증가시킴이 없이 향상 된 항종양, 항바이러스 또는 면역조절 응답을 가져오는 것을 특징으로 하는 방법.
- 제 3항에 있어서, 잘못 짝지은 dsRNA는 환자의 체액을 기준하여 0.01-1,000ug/ml의 농도의 함량으로 투여되며, 인터류킨-2는 환자의 체중을 기준하여 약 102-106IL-2/kg의 농도의 당량으로 투여되는 것을 특징으로 하는 방법.
- dsRNA 및 림포킨을 상대 농도로 도시 또는 연속적으로 투여하여 광잉의 dsRNA 또는 인터류킨에 있어서의 독성을 증가시킴이 없이 기관내에 NK 및 LAK 세포의 향상된 수준을 가져오는 것을 특징으로 하는 치료 조성물.
- 제7항에 있어서, 사클로옥시지나제 활성제를 억제하는 물질을 또한 포함하는 것을 특징으로 하는 치료 조성물.
- 제8항에 있어서, 상기 억제제는 NK 세포 감소 조절 메카니즘을 억제하는 것을 특징으로 하는 치료 조성물.
- 상기 항 중 어느 한 항에 있어서, 상기 dsRNA는 잘못 짝지은 dsRNA이며, 바람직하게는 rIn.(C12U)n의식을 가지는 것을 특징으로 하는 치료 조성물.
- 상기 항중 어느 한 항에 있어서, 상기 림포킨은 인터페론(바람직하게는 알파 인터페론), 또는 인터류킨(바람직하게는 인터류킨 2) 인 것을 특징으로 하는 치료 조성물.※참고사항:최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2136887A | 1987-03-03 | 1987-03-03 | |
US21,368 | 1987-03-03 | ||
US021368 | 1987-03-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR880010776A true KR880010776A (ko) | 1988-10-24 |
KR960008009B1 KR960008009B1 (ko) | 1996-06-19 |
Family
ID=21803798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019880002204A KR960008009B1 (ko) | 1987-03-03 | 1988-03-02 | 인터류킨 및 이중-가닥 rna를 포함하는 상승작용화 조성물 |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0281380B1 (ko) |
JP (1) | JPH0713024B2 (ko) |
KR (1) | KR960008009B1 (ko) |
CN (1) | CN1054509C (ko) |
AT (1) | ATE130760T1 (ko) |
AU (2) | AU1256588A (ko) |
CA (1) | CA1336810C (ko) |
DE (1) | DE3854726T2 (ko) |
DK (1) | DK113188A (ko) |
ES (1) | ES2082749T3 (ko) |
FI (1) | FI880961A (ko) |
IE (1) | IE75895B1 (ko) |
IL (1) | IL85603A (ko) |
NO (1) | NO880946L (ko) |
NZ (1) | NZ223720A (ko) |
PH (1) | PH24467A (ko) |
PT (1) | PT86879B (ko) |
RU (1) | RU1836103C (ko) |
ZA (1) | ZA881512B (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA881639B (en) * | 1987-03-23 | 1989-02-22 | Hem Res Inc | Treatment of human viral infection by dsrna combined with viral inhibitors |
DK0405315T3 (da) * | 1989-06-30 | 1995-09-25 | American Cyanamid Co | Anvendelse af et fagocyt-aktiverende stof: LPS eller IL-2 til fremstilling af et lægemiddel til behandling af Staphylococcus aureus-infektioner hos køer |
FR2766715B1 (fr) * | 1997-08-04 | 2001-02-16 | Scras | Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale |
FR2768344B1 (fr) * | 1997-08-26 | 2001-02-16 | Scras | Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale |
FR2768345B1 (fr) * | 1997-09-17 | 2001-05-04 | Scras | Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale |
TW589189B (en) * | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
BRPI9908967B1 (pt) | 1998-03-20 | 2017-05-30 | Benitec Australia Ltd | processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta |
CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
WO2006054129A1 (en) * | 2004-11-19 | 2006-05-26 | Institut Gustave Roussy | Improved treatment of cancer by double-stranded rna |
EP2116602A1 (en) | 2008-05-07 | 2009-11-11 | Institut Gustave Roussy | Combination products for treating cancer |
US20130195919A1 (en) | 2010-03-05 | 2013-08-01 | President And Fellows Of Harvard College | Induced dendritic cell compositions and uses thereof |
CN106794246B (zh) | 2014-08-08 | 2021-10-15 | OncoQuest制药有限公司 | 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能 |
CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0113162B1 (en) * | 1982-09-16 | 1989-07-19 | Hem Research, Inc. | Anti-proliferative action of dsnras on tumor cells |
CA1326450C (en) * | 1985-08-26 | 1994-01-25 | William A. Carter | Modulation of aids virus-related events by double stranded rnas (dsrnas) |
-
1988
- 1988-02-29 PH PH36569A patent/PH24467A/en unknown
- 1988-03-01 CA CA000560249A patent/CA1336810C/en not_active Expired - Fee Related
- 1988-03-01 IL IL85603A patent/IL85603A/xx not_active IP Right Cessation
- 1988-03-02 NZ NZ223720A patent/NZ223720A/en unknown
- 1988-03-02 PT PT86879A patent/PT86879B/pt not_active IP Right Cessation
- 1988-03-02 EP EP88301821A patent/EP0281380B1/en not_active Expired - Lifetime
- 1988-03-02 KR KR1019880002204A patent/KR960008009B1/ko not_active IP Right Cessation
- 1988-03-02 IE IE58888A patent/IE75895B1/en not_active IP Right Cessation
- 1988-03-02 DK DK113188A patent/DK113188A/da not_active Application Discontinuation
- 1988-03-02 DE DE3854726T patent/DE3854726T2/de not_active Expired - Fee Related
- 1988-03-02 AT AT88301821T patent/ATE130760T1/de not_active IP Right Cessation
- 1988-03-02 FI FI880961A patent/FI880961A/fi not_active Application Discontinuation
- 1988-03-02 ES ES88301821T patent/ES2082749T3/es not_active Expired - Lifetime
- 1988-03-02 JP JP63047655A patent/JPH0713024B2/ja not_active Expired - Fee Related
- 1988-03-02 AU AU12565/88A patent/AU1256588A/en not_active Abandoned
- 1988-03-03 RU SU884355416A patent/RU1836103C/ru active
- 1988-03-03 NO NO880946A patent/NO880946L/no unknown
- 1988-03-03 ZA ZA881512A patent/ZA881512B/xx unknown
- 1988-03-03 CN CN88101697A patent/CN1054509C/zh not_active Expired - Fee Related
-
1992
- 1992-05-12 AU AU16189/92A patent/AU1618992A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1054509C (zh) | 2000-07-19 |
NO880946D0 (no) | 1988-03-03 |
DE3854726D1 (de) | 1996-01-11 |
DK113188D0 (da) | 1988-03-02 |
EP0281380B1 (en) | 1995-11-29 |
EP0281380A3 (en) | 1989-09-27 |
PH24467A (en) | 1990-07-18 |
CN1032296A (zh) | 1989-04-12 |
IL85603A0 (en) | 1988-08-31 |
PT86879B (pt) | 1992-05-29 |
IL85603A (en) | 1993-05-13 |
RU1836103C (ru) | 1993-08-23 |
AU1256588A (en) | 1988-09-01 |
PT86879A (pt) | 1988-04-01 |
KR960008009B1 (ko) | 1996-06-19 |
DE3854726T2 (de) | 1996-07-25 |
FI880961A (fi) | 1988-09-04 |
NZ223720A (en) | 1991-07-26 |
EP0281380A2 (en) | 1988-09-07 |
ES2082749T3 (es) | 1996-04-01 |
CA1336810C (en) | 1995-08-29 |
DK113188A (da) | 1988-09-04 |
IE75895B1 (en) | 1997-09-24 |
AU1618992A (en) | 1992-08-06 |
ATE130760T1 (de) | 1995-12-15 |
JPS63295514A (ja) | 1988-12-01 |
IE880588L (en) | 1988-09-03 |
ZA881512B (en) | 1988-11-30 |
FI880961A0 (fi) | 1988-03-02 |
NO880946L (no) | 1988-09-05 |
JPH0713024B2 (ja) | 1995-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880010776A (ko) | 림포킨 및 이중-가닥 rna의 상승 작용화 조성물 | |
GEP19981482B (en) | Use of 1,3 - Oxatiolan Nucleozides Analoges for Treatment of Hepatitis B | |
JPS6425A (en) | Medicinal composition for treating hiv infection containing dsrna and reverse transcriptase inhibitor | |
NZ226005A (en) | Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof | |
Marx | Natural Killer Cells Help Defend the Body: Immunologists take a new look at immune surveillance and interferon action in the light of natural killer activity | |
DK607885A (da) | Medikamentpraeparater med formindsket giftighed | |
ATE170075T1 (de) | Antivirales arzneimittel enthaltend prostratin | |
De Clercq et al. | Synergism in the antitumor effects of type 1 and type II interferon in mice inoculated with leukemia L1210 cells | |
Mowshowitz et al. | Interferon and Cis-DDP: combination chemotherapy for P388 leukemia in CDF1 mice | |
Gresser | How does interferon inhibit tumour growth? | |
Maheshwari et al. | Interferon inhibits Aspergillus fumigatus growth in mice: an activity against an extracellular infection | |
Kohl | Additive effects of acyclovir and immune transfer in neonatal herpes simplex virus infection in mice | |
Fleischmann et al. | Systemic effects of orally administered interferons and interleukin-2 | |
GRESSER | Interferon therapy: Obvious and not so obvious applications | |
ES2052579T3 (es) | Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida. | |
ES2103811T3 (es) | Terapia antiviral. | |
Kohl | Stimulation of human natural killer cytotoxicity and protection of mice from infection due to herpes simplex virus by recombinant human leukocyte interferon | |
KR910000182A (ko) | 항바이러스성 약제학적 조성물 | |
KOREN et al. | Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin-2 | |
Riveau et al. | Modulation of interferon-α-induced human monocyte activation by a muramyl dipeptide derivative | |
Riveau et al. | Influence of murametide on human blood leukocyte functions and their membrane antigens | |
TW217986B (en) | Compositions for the treatment of infection and disease caused by HBV | |
Poillart et al. | Potentiation by murametide of interferon antiviral activity against encephalomyocarditis infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20031110 Year of fee payment: 8 |
|
LAPS | Lapse due to unpaid annual fee |